DiagnaMed Holdings Corp., a leading provider of technology solutions for the hydrogen and life sciences industries, has successfully closed a private placement. The company issued 13,250,333 units at $0.03 per unit, generating total proceeds of $397,510. Each unit includes a common share and a common share purchase warrant. The offering's net proceeds will support the research, development, and commercialization of hydrogen production and monitor technology, along with the BRAIN AGE® Brain Health AI Platform, in addition to general corporate needs. Chairman and CEO Fabio Chianelli personally subscribed for 850,000 units, contributing $25,500 to the company's funds. This insider participation qualifies as a related party transaction but is exempt from certain formal valuation and approval requirements due to the transaction's size relative to the company's market capitalization. DiagnaMed did not file a material change report in advance due to the recent determination of insiders' participation, which remained compliant with regulations.